Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zefeng Xu

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Blood Cancer Journal|January 17, 2018
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia responseXueping Luo, Zefeng Xu, Bing Li, et al.
British Journal of Haematology|December 2, 2017
The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the IPSS-R?Bing Li, Jinqin Liu, Zefeng Xu, et al.
Leukemia|July 12, 2025
Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1<sup>S34F</sup> mutant myelodysplastic neoplasmsWenjun Zhang, Bing Li, Jinqin Liu, et al.
Cancer Medicine|March 6, 2025
Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q DeletionYanan Chang, Linlin Liu, Chenghua Cui, et al.
Blood Cancer Journal|June 22, 2026
Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I studyZefeng Xu, Jinqin Liu, Zhenya Hong, et al.
American Journal of Hematology|February 27, 2026
Sex-Related Differences in Clinical Features, Inflammatory Cytokines, Mutation Topography, Outcomes, and Prognostic Models in Patients With Myeloproliferative NeoplasmsSongyang Zhao, Xin Wang, Bing Li, et al.
Hematological Oncology|August 15, 2021
Is race important in genomic classification of hematological neoplasms?Huijun Huang, Junying Wu, Tiejun Qin, et al.
Hematological Oncology|October 20, 2022
Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariatesJunying Wu, Wenjun Zhang, Peihong Zhang, et al.
Blood|December 17, 2025
The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasmsYiru Yan, Jinqin Liu, Songyang Zhao, et al.
Leukemia|May 7, 2024
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosisFuhui Li, Tiejun Qin, Bing Li, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Blood Cancer Journal|January 17, 2018
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia responseXueping Luo, Zefeng Xu, Bing Li, et al.
British Journal of Haematology|December 2, 2017
The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the IPSS-R?Bing Li, Jinqin Liu, Zefeng Xu, et al.
Leukemia|July 12, 2025
Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1<sup>S34F</sup> mutant myelodysplastic neoplasmsWenjun Zhang, Bing Li, Jinqin Liu, et al.
Cancer Medicine|March 6, 2025
Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q DeletionYanan Chang, Linlin Liu, Chenghua Cui, et al.
Blood Cancer Journal|June 22, 2026
Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I studyZefeng Xu, Jinqin Liu, Zhenya Hong, et al.
American Journal of Hematology|February 27, 2026
Sex-Related Differences in Clinical Features, Inflammatory Cytokines, Mutation Topography, Outcomes, and Prognostic Models in Patients With Myeloproliferative NeoplasmsSongyang Zhao, Xin Wang, Bing Li, et al.
Hematological Oncology|August 15, 2021
Is race important in genomic classification of hematological neoplasms?Huijun Huang, Junying Wu, Tiejun Qin, et al.
Hematological Oncology|October 20, 2022
Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariatesJunying Wu, Wenjun Zhang, Peihong Zhang, et al.
Blood|December 17, 2025
The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasmsYiru Yan, Jinqin Liu, Songyang Zhao, et al.
Leukemia|May 7, 2024
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosisFuhui Li, Tiejun Qin, Bing Li, et al.
Pageof 13